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DNA-array of gene variants in venous leg ulcers:
Detection of prognostic indicators
Donato Gemmati, PhD,a,b Federica Federici, PhD,a,b Linda Catozzi, PhD,a,b Sergio Gianesini, MD,b
Giovanna Tacconi, MD,b Gian L. Scapoli, MD,a,b and Paolo Zamboni, MD,b Ferrara, Italy
Objective: Wound healing in venous leg ulcer (VLU) is a multi-step process involving complex pathways. Scanty
knowledge at molecular level hinders clinical assessment and treatment. Anomalous handling of local iron overload, as
well as unbalancing in matrix metalloproteinases (MMPs) and transglutaminase, has a recognized role in VLU
establishment. We selected a number of single nucleotide polymorphisms (SNPs) in candidate genes (HFE, FPN1,
MMP12, and FXIII) involved in VLU to identify potentially prognostic markers by means of DNA-array technology.
Methods and Results: The DNA-array-genotyping was assessed in 638 subjects for the following SNPs: HFE (C282Y,
H63D), FPN1 (8CG), MMP12 (82AG) and FXIII (V34L). Of the subjects, 221 were affected by VLU (171 primary
and 50 post-thrombosis), 112 by severe chronic venous disease (CVD) (CEAP, C3-C4), while 305 were matched healthy
controls. The HFE and FXIII SNPs had been previously genotyped by conventional polymerase chain reaction
(PCR)-methods on the same group of subjects (J Vasc Surg 2005;42:309; J Vasc Surg 2006;44:554; J Vasc Surg
2006;44:815). For the purpose of DNA-array, they were re-genotyped by means of array-techniques resulting in a 100%
matching. Intergroup statistical comparisons were performed. In the risk computation, the FPN18GG genotype had an
overall CVD risk of 4.3 (95% CI, 1.6-12) and a VLU risk of 5.2 (95% CI, 1.9-15) virtually the same among primary VLU
(4.98; 95% CI, 1.82-14.9). The MMP12 82AA genotype had a VLU risk of 1.96 (95% CI, 1.18-3.2) only in primary
VLU (P .01). In the genotype-ulcer size association studies, from a subgroup of 167 cases, we observed a smaller mean
ulcer size in theMMP12GG-genotype compared with the other genotypes (P .001). Combining the present results with
our previous published data on the same population, we suggest them to apply as tentative prognostic indicators in
primary CVD.
Conclusion: By analyzing simultaneously selected SNPs, it might be possible to glean precious information in predicting
VLU onset or in stratifying patients according to their potential to heal. Although significant, our findings must be
considered preliminary and the proposed prognostic indicators considered with caution, before ulterior more extensive
studies in different populations can eventually confirm the present findings. ( J Vasc Surg 2009;50:1444-51.)
Clinical Relevance: The DNA-array evaluation could be added to clinical CVD assessment. By analyzing simultaneously
selected SNPs, it is possible to have precious information in predicting VLU onset or in stratifying patients according to
their potential to heal. Prevention program in primary CVD could be improved by using DNA-array evaluation in initial
patient assessment. Our results must be handled with extreme caution before considering them as prognostic indicators
in VLU, and further larger studies in different populations are mandatory.Among the major complications of chronic venous
disease (CVD), venous leg ulcer (VLU) is one of the most
severe. It accounts for a significant proportion of lower
extremity wounds and is a widespread pathologic condition
in developed countries.1,2 Several conditions influence and
exacerbate VLU such as diabetes mellitus, rheumatoid ar-
thritis, trauma, sickle cell disease, vasculitis, and skin tumor.
Both in Europe and in the United States, the prevalence of
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1444VLU is about 1%, with relative high costs for assistance and
treatment. The cost is estimated at $1 billion per annum in
the United States, while in the United Kingdom 14% of
health costs are apportioned to wound care.3 Gender, age,
ethnicity, and environment strongly influence penetrance
of disease.2,4,5 Regardless of the clinical strategy used,
evident variations in the outcome in patients with similar
disease pattern and treatment are observed.6 Therefore,
apart from CVD, increasing age and female gender, irrefut-
able evidence of predisposition to VLU is still limited and
elusive. As regards to genetics, candidate genes could po-
tentially be those involved in inflammatory processes, fibro-
blast growth factors, angiogenesis, or apoptosis. However,
a recent paper comparing healing vs nonhealing lesion
expression profiles found that none of the assumed genes
involved in wound repair (ie, platelet-derived growth fac-
tors [PDGF] or keratinocyte growth factor [KGF]) were
significantly downregulated in nonhealing ulcers.7 In recent
years, hypothetical molecular mechanisms have been sug-
gested, by means of which local iron overload facilitates the
development of VLU. This model has been compared to
other iron-driven lesions in neurodegenerative disorders.8,9
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and VLU are available in literature.10-13 Our group re-
cently acknowledged the patho-physiological role of iron
deposition, iron trafficking genes, and transglutaminases in
VLU establishment,14-20 recognizing a strong genetic
component in ulcer pathogenesis.21,22 In particular, the
commonHFE-C282Y andH63D SNPs play a role, respec-
tively, in the risk of venous ulceration in primary CVD and
in the modulation of the lesion onset.14,15 The same gene
variants also show significant effects in healing time after
superficial venous surgery.17,21 On the other hand, we
found that additional SNPs could act as protective factors.
Such is the case of the coagulation factor XIII gene (ie,
FXIII V34L and P564L) acting on extracellular matrix
(ECM) components and fibroblasts. Those variants show in
vivo and in vitro positive effects on wound healing, tissue
repairing, and remodelling.17-21
In the present paper, we investigated two additional SNPs
in CVD patients, one in the promoter of the ferroportin gene
(FPN1; 8CG), and another in the promoter of the matrix
metalloproteinase 12 gene (MMP12;82AG).
To date, no data are available concerning the role of
FPN1 gene variants in CVD. The FPN1 8CG polymor-
phism is extremely close to the iron responsive element
(IRE) of the gene, thus potentially interfering with FPN1
expression.23-26 The82AG polymorphism in theMMP12
gene influencing promoter activity could plausibly play a
role in leg ulcer progression as well as in other complex
diseases by ECM degradation.27-32
The new data obtained from the present investigation
have beenmerged and computed together with previous data
recently publishedbyus onHFE andFXIIISNPs14,17,18,20 to
propose prognostic markers by means of a DNA-array ap-
proach in CVD.
SUBJECTS AND METHODS
We investigated a total of 638 subjects, classified as per
Fig 1. Whole cohort of subjects investigated. C3-C6 according
to CEAP international classification of CVD. CVD, Chronic ve-
nous disease; VLU, venous leg ulcer.the scheme in Fig 1.Case group. Patients (n  333), of whom 65% were
females affected by CVD, had a mean age of 60.5  14.5
years. Among these, 221 had C5-C6 VLU (171 primary
and 50 post-thrombosis) and 112 had C3-C4 phenotype.
All patients underwent clinical and duplex scanning exam-
ination. This investigation was conducted in conformity
with consensus statement criteria and the methodology
previously described.33-35 This approach enabled us to
separate primary superficial from post-thrombotic cases
and/or with deep venous reflux, as well as to identify
patients with peripheral arterial disease.
Patient selection was put in place by means of strictly
applied exclusion criteria17 (detailed below) in order to
exclude any other comorbidity factor potentially involved
in ulcer wound healing:
● diabetes;
● peripheral arterial disease and/or ankle brachial index
0.9;
● hemolytic anemia and/or iron-deficiency anemia
and/or malnutrition;
● inability to walk;
● severe cardiac and/or hepatic and/or renal and/or
pulmonary insufficiency;
● or chronic administration of cortisones for chronic
inflammatory disease and/or autoimmune disease.
Subsequently, and prior to any treatment, the ulcerated
area was assessed by means of software for calculating
irregular areas (Visitrak Capture, Smith & Nephew UK
Limited, London, UK). The age of ulcer onset in the
groups with different genotypes was recorded. We did not
utilize a specific cut-off to determine patients with early or
late ulcer onset. The age was that recorded during the
patients’ initial consultation at the Vascular Disease Centre
of the University-Hospital of Ferrara. In the event patients
developed an ulcer before the end of data collection, their
status was duly modified in our database and no other
follow-up was made. Patients were recruited during the
period from 2002 to 2005, as previously reported. Al-
though significant, we could not account for occupational
status or multiple pregnancies in women as confounders in
this analysis.
Healthy controls. The control group consisted of
305 healthy subjects with no history of vascular disease and
recruited from the blood donor file of Ferrara Hospital.
They were matched by age, gender, and geographic origin
with the CVD cases. All subjects enrolled in the study gave
informed consent, and the survey was approved by the
University-Hospital Ethics Committee of Ferrara.
DNA extraction and PCR conditions. The DNA
was isolated from peripheral frozen whole blood by using
the automated DNA extraction and purification robot
(BioRobot EZ1 system, QIAGEN, Hilden, Germany),
which performs the fully automated extraction and purifi-
cation of nucleic acids using magnetic bead technology.
The PCR-protocol for the simultaneous amplification
of the gene regions containing C282Y andH63D substitu-
tions in theHFE gene, the8CG substitution in the FPN1
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promoter, and theV34L substitution in the FXIII gene was
carried out as follows: an initial 10 minutes at 94°C fol-
lowed by 35 cycles of 95°C for 30 seconds, 56°C for 20
seconds, and 72°C for 90 seconds. The PCR cycles were
performed in a Peltier Thermal Cycler apparatus (PTC-
200; M J Research, Inc, Watertown, Mass) and were com-
pleted with a final extension step of 5 minutes at 72°C. The
multiplex PCR-reaction was performed in 100 l final
volume containing 100 ng of genomic DNA, 20 M
dNTPs, 1.5 mM MgCl2, 10 mM Tris-HCl (pH 8.3), 50
mM KCl, 15 pmol of each primer, and 2.0 U of recombi-
nant DNA polymerase (AmpliTaq Gold, Applied Biosys-
tems, Branchburg, NJ).
Table I (A and B) shows the sequences of the different
pairs of primers needed for PCR and the oligos/probes
utilized for genotyping according to the five polymor-
phisms in the study.
Genotyping on the Nanogen system. Amplicons
were genotyped by the Nanogen microchip system (Nano-
chip Molecular Biology Workstation, Nanogen Corporate,
San Diego, Calif). A volume of 10-20 l containing the
Table IA. Sequences of the different couples of PCR prim
SNP
FPN1 8CG (Fw) Bio CCAGTT
FPN1 8CG (Rv) CATCCT
HFE C282Y (Fw) CGAACC
HFE C282Y (Rv) Bio CCCAAT
HFE H63D (Fw) GTTTGA
HFE H63D (Rv) Bio CCACAT
MMP12 82AG (Fw) Bio GCCTAA
MMP12 82AG (Rv) AGTCAT
FXIII V34L (Fw) GACCTT
FXIII V34L (Rv) Bio ACCCAG
Fw, Forward primer; Rv, reverse primer; Bio, biotinylated primer.
Table IB. Oligonucleotides utilized in the reporter mix
Oligo
FPN1 8CG Discriminator wild type
FPN1 8CG Discriminator mutated
FPN1 8CG Stabilizer
HFE C282Y Discriminator wild type
HFE C282Y Discriminator mutated
HFE C282Y Stabilizer
HFE H63D Discriminator wild type
HFE H63D Discriminator mutated
HFE H63D Stabilizer
MMP12 82AG Discriminator wild type
MMP12 82AG Discriminator mutated
MMP12 82AG Stabilizer
FXIII-A V34L Discriminator wild type
FXIII-A V34L Discriminator mutated
FXIII-A V34L Stabilizer
In Italics are reported the universal tail recognized by the universal reporte
M, indicates A or C; W, indicates A or T.amplicon-mix was mixed with histidine buffer to 50mmol/L final concentration in 60 l final volume. About
100-200 ng of each amplicon were addressed onto the
Nanochip Cartridge (H2-type) by means of the Nanochip
Loader using default parameters. A chemical denaturation
of amplicons, by means of NaOH 0.1N for 5 minutes of
treatment, ended the addressing protocol. Each reporter
mix contained probes (discriminator), stabilizers, and re-
porter oligonucleotides (details published on www.nanogen.
com) specific for each SNP. Hybridization steps and fluo-
rescence scans of the cartridge were carried out by the
Nanochip Reader. An optimized hybridization touchdown
protocol was determined for the analysis of each polymor-
phism. The instrumentation and general protocols fol-
lowed are detailed in previous reports.36,37 About 20% of
samples were loaded and analyzed in duplicate, and het-
erozygous controls were always included in each assay.
Quantitative analysis and genotype designation were real-
ized by using specific software supplied by Nanogen and
both were set at the diagnostic level.
Genotype confirming procedure. Haplotypes were
confirmed by re-genotyping about 20% of random samples
selected from each different genotype group per specific
ence (5=-3=) Amplicon size
GCACTCCTG 129 bp
GGCGGTTG
GACGTATTGCC 183 bp
TTTCTCAGCTCCT
TTTGGGCTACG 115 bp
CTTGAAATTCT
CTGAACTGTTCC 129 bp
TTGTTTGCATGTT
AGTCAAAAATGTC 195 bp
GGTGGGGAA
Sequence
TGAGTCCGAACATTGAG-AAAGGTCATGACACTAG-3=
CAGTATATCGCTTGACA-AAAGGTCATGACACTAC-3=
CGACCCCGCTGGCTCTTCTGCGGCTGCTA-3=
TGAGTCCGAACATTGAG-AGAGATATACGTG-3=
CAGTCTATCGCTTGACA-CAGAGATATACGTA-3=
CMGGTGGAGCACCCAGGCCT-3=
TGAGTCCGAACATTGAG-TCGTGTTCTATGATC-3=
CAGTATATCGCTTGACA-TCGTGTTCTATGATG-3=
TGAGWGTCGCCGTGTGGAGCCCCGAA-3=
TGAGTCCGAACATTGAG-TTTGGGATGATATCAACTA-3=
CAGTATATCGCTTGACA-TTTGGATGATATCAACTG-3=
GAGTCACTCATAGGATTCATATTCACAGAACCCGG-3=
TGAGTCCGAACATTGAG-TTTGCTTCAGGGCG-3=
CAGTATATCGCTTGACA-TTTAGCTTCAGGGCT-3=
GGTGCCCCGGGGCGTCAC-3=ers
Sequ
CCTT
CTCT
TAAA
AGAT
AGC
CTGG
GTTC
GCTT
GTAA
AGT5=-C
5=-G
5=-G
5=-C
5=-G
5=-C
5=-C
5=-G
5=-A
5=-C
5=-G
5=-T
5=-C
5=-G
5=-T
r.polymorphism by means of enzymatic restriction or direct
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procedure. There were no discrepancies between genotypes
determined in duplicate and/or by different methods.
Statistical analysis. A retrospective cross-sectional
study was performed. Statistical differences among groups
were assessed by the t test and the 2 test, respectively, for
mean value and genotype distribution comparisons. Where
appropriate, Yates’ correction or Fisher’s exact test were
applied. Odds ratios (ORs) and 95% confidence intervals
(95%CIs) were calculated by conditional logistic regression
models, accounting variables and other confounding fac-
tors such as gender, age, andweight. In addition, themodel
accounts for a mutual adjustment of the different SNPs
considered. The reported values were obtained by multiple
comparison tests. Any P values .05 were considered sta-
tistically significant. All analyses were performed using Sys-
tat V.5.0 (Systat Inc, Evanston, Ill) and SPSS Statistical
Package (SPSS Inc, Chicago, Ill).
RESULTS
Computing VLU risk.
FPN1 8CG. Table II shows the computing of VLU
risk assessed in the group of VLU cases (n  221) com-
pared to a subset of completely matched healthy controls
(OR 5.2; 95% CI, 1.9-15; P .005). This was obtained
by the comparison of the homozygous genotype in the
FPN1 gene (GG) with the counterpart wild-type genotype
(CC). Comparing the GG condition with the rest of the
genotypes, the risk value remained stable and signific-
ance increased (OR  4.4; CI 95%, 1.55-12.1; P  .002).
In addition, the comparison between the subsets of C5-C6
patients (ie, primary vs post-thrombotic VLU) did not
show significant associations to FPN1 genotypes, although
an over-representation of the GG-homozygotes was present
among primary VLU (9.35% vs 6.0%; P .05). Consider-
ing the C5-C6 vs C3-C4 comparison, (ie, CVD patients
with ulcer vs those without), it has obtained a significant
over-representation of G-carriers among C5-C6 (43% vs
31.25%). This yielded an associated risk in developing the
lesion of 1.7; (95% CI, 1.03-2.7; P  .045).
Table III shows the computing of VLU risk assessed in
the subgroup of primary VLU cases (n 171) compared to
a subset of completely matched healthy controls (OR 
4.98; 95% CI, 1.82-14.9; P  .005). This was obtained
from the comparison of the homozygous genotype in the
FPN1 gene (GG) with the counterpart wild-type genotype
Table II. All VLU vs controls
FPN1 8CG Cases (n  221) Controls (n  221)
CC 126 (57.0) 148 (67.0)
CG 76 (34.0) 68 (30.8)
GG 19 (8.6) 5 (2.3)
P value .005
OR (95% CI) 5.2 (1.9-15)
VLU, Venous leg ulcer; OR, odds ratio; CI, confidence interval.(CC). Comparing the GG condition with the rest of thegenotypes, risk value remained stable and significance in-
creased (OR  4.7; 95% CI, 1.6-14.1; P  .002).
In addition, the comparison of all CVD patients (n 
333) with the healthy controls (n  305) yielded an in-
creased risk of 4.3 (95% CI, 1.6-12; P  .002).
MMP12 82AG. Considering the MMP12 polymor-
phism, a different genotype distribution was observed (P
.010) comparing primary VLU vs matched healthy controls
(ie, cases: AA n 139 [81.3%], AG n 26 [15.2%], GG n
6 [3.5%] vs controls: AA n  118 [69%], AG n  49
[28.7%], GG n  4 [2.3%]). In addition (Table IV),
considering only the homozygous AA-genotype, this was
over-represented among primary VLUs with an associated
risk of 1.96 (95% CI, 1.18-3.22; P  .010).
HFE C282Y and H63D. Risk assessment in the
groups of patients investigated fully resembled that of our
previous reports.14,17 In the present survey, C2282Y
yielded a significant overall risk for CVD (OR  4.5; 95%
CI, 1.3-14.9; P  .001) and among primary CVD the risk
further increased (OR 6.5; 95% CI, 1.5-26.5; P .001)
(Table V). Conversely, the H63D gene variant did not
show increased risk, but was responsible for an earlier ulcer
onset among primary CVD (wild type vs 63D-carriers: 64
years 15 vs 55 years 14; P .0001) in conformity with
Table III. Primary VLU vs controls
FPN1 8CG Cases (n  171) Controls (n  171)
CC 96 (56.1) 115 (67.2)
CG 59 (34.5) 52 (30.4)
GG 16 (9.4) 4 (2.3)
P value .005
OR (95% CI) 4.98 (1.82-14.9)
VLU, Venous leg ulcer; OR, odds ratio; CI, confidence interval.
Table IV. Primary VLU vs controls
MMP 82AG Cases (n  171) Controls (n  171)
AA 139 (81.3) 118 (69.0)
AG 26 (15.2) 49 (28.7)
GG 6 (3.5) 4 (2.3)
P value .01
OR (95% CI) 1.96 (1.18-3.22)
VLU, Venous leg ulcer; OR, odds ratio; CI, confidence interval.
Table V. Primary VLU vs CVD (C3C4)
HFE C282Y Cases (n  171) Controls (n  112)
CC 153 (89.5) 110 (98.2)
CY 17 (9.9) 2 (1.8)
YY 1 (0.6) 0 (0.0)
P value .001
OR (95% CI) 6.5 (1.5-26.5)
CVD, Chronic venous disease; VLU, venous leg ulcer; OR, odds ratio; CI,
confidence interval.our previous reports.14,15
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FPN1 8CG. In a subgroup of VLU patients (n 
167), the lesion size was available at the recruitment step.
Considering the relationships between a specific FPN1
genotype and the relative mean ulcer size, it has obtained a
nonsignificant trend (P  .30) towards increased size and
the G-allele (CC, n  101: 10  19.26 cm2; CG, n  56:
12.0  25.6 cm2; GG, n  10: 13.6  14.2 cm2).
MMP12 82AG. In the same subgroup of patients,
we found a significant (P  .001) smaller mean size in the
subgroup of patients carrying the MMP12 82GG geno-
type (n 6) when compared with the remaining genotypes
(82AAAG; n  161). The mean ulcer size in the
patients with 82GG genotype was 5.4  2.0 cm2 and in
the remaining patients was 11.1  17.1 cm2 (Fig 2).
FXIII V34L. The same subgroup yielded ulcer size
stratification as shown in Fig 3: the size of the lesion was
inversely related to the number of L34 allele in the geno-
type of patient (P trend  .001).
Previous data published on HFE and FXIII
SNPs. As reported, the data on HFE and FXIII gene
polymorphisms obtained in this study by the DNA-array
procedure, fully matched previously published data ob-
tained by conventional PCR techniques.14,17,18,20 For this
reason, only findings concerning FPN1 and MMP12 SNPs
are reported in detail together with significant new findings
for the remaining genes investigated. Nevertheless, the
Method section of this article contains complete DNA-
array procedures for all the SNPs computed. This is because
the sequence of the oligonucleotides and the technical
procedure utilized in the present study have never been
published in literature before and the tentative investigative
approach for VLU clinical assessment is based on the entire
DNA-array evaluation.
Combined analysis. Of the 333 patients with CVD,
3% (n  10) carried the HFE 282Y and the FPN1 8G
polymorphic allele in combination (ie, cases carrying at
least two polymorphic alleles in the two different genes).
Fig 2. Relationships between MMP12 82AG polymorphism
and venous ulcer size. Mean and SD values are reported. The P
value is obtained by t test.Although extremely low, double carriers were exclusivelydistributed among the 221 VLU cases increasing the rate
from 3% to 4.5%. The comparison of CVD cases with ulcer
(C5-C6) vs those without (C3-C4), yielded a borderline
significant over-representation of double carriers among
ulcerated patients (P  .052).
Similarly, among the VLU patients in which the lesion
size was available, those carrying in combination the
MMP12 82G and the FXIII 34L allele (n  17), had a
nonsignificant (P .065) smaller mean ulcer size (9.0 cm2
10) when compared to the 69 double wild-type cases
(MMP1282AA/FXIII 34VV), (15.5 cm2 17.5). Both
findings, though borderline in statistical significance due to
the low sample size, are in conformity with the protective
role ascribed to the same alleles when considered in single
analysis.
Investigative approach to VLU clinical assessment
by DNA-array. Merging data obtained in the present
survey (FPN1 8CG and MMP12 82AG) with those
from additional SNPs (HFE C282Y, H63D, and FXIIIA
V34L) reported in our previous investigations, we propose a
provisional list of prognostic indicators in primary CVD (Ta-
ble VI).
DISCUSSION
Findings from the present study evidence that, bymeans
of DNA-array evaluation, crucial information on VLU poten-
tially useful for clinical management can be obtained. Recent
studies on complementary DNA-microarray have demon-
strated diversity in genetic expression of healing vs nonheal-
ing wounds.7 An altered expression was found in genes that
code for structural factors, mediators of inflammation and
apoptotic pathways. The authors demonstrated that heal-
ing and nonhealing leg ulcers are characterized by a com-
pletely different genetic physiology. Similarly, our study
Fig 3. Relationships between FXIII V34L polymorphism and
venous ulcer size. Mean and SD values are reported. The P value is
obtained by test for trend.aimed to identify a particular genetic background which,
IVA s
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sided clinical phenotype characteristic of complex diseases
such as CVD and VLU.
Equally effective is the genome wide association studies
(GWAS) approach which identifies relevant patterns of
numerous SNPs to predict future disease states and to
evaluate gene patterns that relate to multiple phenotypes of
complex diseases. Similarly, our aim, though limited, was to
select SNPs of candidate genes potentially involved in the
pathogenesis of VLU. This was done on the basis of accu-
rate knowledge of the clinical and physiopathologic find-
ings relative to the disease (see previous studies). Results
from the present study, combined with previously investi-
gated gene variants and selected clinical findings, proposes
a molecular tool for identifying patients with potentially
delayed healing or nonhealing ulcers. Although accounting
just in part for the multipathway mechanisms, it could be
valid in complex diseases and act as inducement for more
extensive future investigations.
The gene markers identified by the DNA-array, are
involved in susceptibility (HFE, FPN1; MMP12), healing
time (FXIII), ulcer size (FXIII andMMP12), and response
to surgery (FXIII). Although associated with appreciable
statistical potential, additional genes and/or SNPs should
be investigated in wider epidemiologic studies and con-
firmed in different populations to strengthen the potential
of this molecular tool.
The selection of genes to investigate needs to be imple-
mented on the basis of in-depth knowledge of the patho-
physiologic grounds of the complex disease, and that of the
gene variants on the basis of their associated phenotype, if
known.
The fact that iron overload has a role in VLU,
prompted us to investigate HFE and FPN1 gene variant.
Although they were considered asymptomatic mutations
for systemic diseases,38-40 we investigated them in combi-
nation with an acquired condition: CVD. In patients af-
fected by severe CVD, the overlapping of local iron over-
load and the HFE mutations facilitates the occurrence
of skin lesions and significantly anticipates the onset age of
the ulcerative disease.14,15 TheHFEmutation modifies the
Table VI. Summary of the main findings in the present an
SNPs
VLU risk
(primary CVD)
Lesion onset
(primary CVD
HFE C282Y Y-allele1 risk (6-7	) —
HFE H65D — D-allele2 age o
(
10 y)
FPN1 8CG GG-genotype1 risk (
5	) —
MMP12 82AG AA-genotype1 risk (
2	) —
FXIII V34L — —
HFE/FPN1 Y/G-carriers1 risk (NS) —
FXIII/MMP12 — —
CVD, Chronic venous disease; CHIVA, hemodynamic correction after CHstability of the ferritin deposits as well as the efficiency of thehepcidin regulation system, leading to increased iron ef-
flux.41-43 We hypothesize that tissue lesion generates from
enhanced iron release and consequent free radical produc-
tion. Its role and mechanism in VLU has been widely
described.15
Similarly, we decided to investigate the FPN1 gene
(locus 2q32) and one of its polymorphisms in the promo-
ter.40 The gene codes for a multiple transmembrane do-
main protein, and as opposed to other iron trafficking
proteins, it is the only one identified exporting iron outside
the cell.23-25 FPN1 SNPs have never been associated to any
specific disease. Expressed by macrophage, the process is
regulated at several different levels. FPN1 mRNA contains
in the 5=-UTR region the IRE sequence which interacts
with the iron regulatory proteins (IRP); it can also be
regulated post-translationally by hepcidin. The existence of
an IRE region in the 5=-UTR of FPN1 results in increased
expression of the protein proportional to cellular iron load-
ing, modulating iron export.26 The marked closeness of
8CG polymorphism to the crucial IRE region prompted
us to investigate its role in VLU. Taking into account our
hypothesis that tissue lesion generates from enhanced iron
release, free radical production, and the pathophysiologic
pathway described for HFEmay also be applicable to FPN1
with the result that the two genes together can interact on
VLU. The significant association we found between8CG
SNP and VLU susceptibility can speculatively be inter-
preted and summarized as follows: (1) A direct role of the
polymorphism in the macrophage membrane as previously
described for HFE C282Y.42,43 Thus, the polymorphism
could hamper the efflux of iron from inside the cell strongly
contributing to increased oxidative stress and cell death; (2)
An indirect role of still unknown molecular defects linked
to 8CG SNP.
MMPs, together with their inhibitors tissue inhibitor of
metalloproteinases (TIMPs), are involved in vascular re-
modeling and vascular disease.28 The regulation of MMP
expression is complex and takes place at both transcrip-
tional and post-transcriptional levels.44
MMP12 (locus 11q22.3), secreted by activated macro-
phages, digests several ECM components which enables
evious studies
Lesion size
Healing time
(after CHIVA) Ref.
— No effect after
correction
(14,17,21)
— — (15,21)
GG-genotype1 size (NS) — This paper
GG-genotype2 size (
2	) — This paper
L-allele2 size (
3.5	) VV-genotype1 HT
(
2	)
(20,17,21)
— — This paper
L/G-carriers2 size (NS) — This paper
urgery; NS, not significant.d pr
)
nsetmacrophages to penetrate injured tissues.27,28MMP12may
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tin, a potent angiogenesis inhibitor. The82AG polymor-
phism in the MMP12 promoter is very close to the tran-
scriptional factor-binding site for AP1. For this reason, it
may influence their specific interactions. The higher pro-
moter activity of the A-allele described above compared to
the G-allele gives expected higher expression levels. Al-
though no basal difference was described between expres-
sions of the two alleles, in transfecting experiments the
response of A-allele is higher when cells are stimulated with
insulin or phorbol myristate acetate.29 Small change in
promoter activity was recorded between the two alleles and
this could be sufficient and have significant effects on
long-staying wounds. Accordingly, chronic higher expres-
sion of MMP12 in wounds of patients with 82A-allele
may be responsible for the significant smaller ulcer size
found in 82GG patients. The controversial fact that we
did not find any risk association with the MMP12 A-allele
(ie, cases with 82AG  82AA genotypes), but only
when the 82A-allele was in the homozygous condition,
might indicate that the A-allele in single copy is not strong
enough to be causative for ulcer onset. However, once the
lesion appears it may modulate the size: AA and AG cases
had a significant larger wound area. Finally, findings on the
association of the polymorphism with coronary artery dis-
ease, cancer, and endometriosis have also been recently
published.29-32
FXIII strengthens the ECM components against unre-
strained MMP proteolysis, favoring in turn fibroblast mi-
gration and proliferation and promoting neoangiogenesis
and healing. The extent of these and additional actions
strictly depends on the associated gene variants.19-21,45 It
could be hypothesized that a significant higher FXIII ac-
tivity (ie, that of the L34-variant) at the wound site, could
better promote wound healing by ameliorating the above-
mentioned pathway resulting in reduced wound size and
shortened wound healing time.17,20
Apart from specific genotypes, the VLU area may also
be influenced by past treatment practiced prior to our first
clinical assessment. With regard to our data, the lesion size
was recorded at the recruitment step before the start of any
surgical or medical treatment. In addition, the cases in
which the lesion area was recorded belonged to a group
with restrictive inclusion criteria, as previously reported,17
this was in order to minimize several confounding factors
masking the genotype effects.
In short, on the basis of the described results, preven-
tion programs in primary CVD could be improved by using
DNA-array evaluation in the initial patient assessment
phase. Clinical practice could be potentially influenced by
these results.22 One example is given by using HFE and
FPN1 SNPs. A positive test for one or both gene variants
would suggest indication and priority for surgical correc-
tion of superficial venous insufficiency while primary vari-
cose veins could be treated more appropriately before any
lesion appears in those patients with a critical gene haplo-
type.21,22,46We conclude that by simultaneous analysis of selected
SNPs, it might be possible to glean important information
for predicting VLU onset stratifying patients according to
their potential to heal.
It should be emphasized, however, that although sig-
nificant, these findings have to be considered as prelimi-
nary. The proposed prognostic indicators should be used
with caution and subjected to further trials on different
populations prior to definitive confirmation.
We thank Dr Kathleen Galvin for the complete revision
of the manuscript.
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